Ocular Oncology and Pathology – Gustav Stålhammar's research group

We conduct clinical and preclinical research to expand knowledge, improve survival and reduce suffering in eye cancer and diseases of the eyelids and lacrimal system.

Gustav Stålhammars forskargrupp
Gustav Stålhammar´s research group

A variety of different tumors can arise in the eye, in the eyelids and in the orbit. Some of these are benign, while others are malignant and very aggressive.

Uveal melanoma is the most common primary intraocular tumor in adults. Almost half of all patients develop metastases even if the eye has been removed. This is believed to be due to so-called micrometastases that leave the primary tumor very early. These micrometastases can remain dormant in their metastatic niche, including the bone marrow and liver, for several years. Once they leave dormancy and start growing, the patient’s prognosis is poor. Uveal melanoma is thereby a cancer disease with unpredictable, high mortality and limited treatment options. We would like to help remedy this. To this aim, we extend current knowledge in the field with clinical and preclinical research. We also develop prognostic test with high accuracy and conduct clinical trials with the aim to prevent the development of metastases.

The most common tumor in children is Retinoblastoma. In national and international collaboration, we research genetic aspects of the disease and evaluate the results of novel treatment regimens.

*
Photo: Gustav Stålhammar

Publications

Selected publications

All publications from group members

Staff and contact

Group leader

All members of the group

Research Projects

We perform translational research in clinical environments and laboratories. As both the affiliated researchers and the infrastructure are exclusively dedicated to ocular oncology and pathology, we aim to achieve and maintain excellence in this area.

News

Ocular Oncology and Pathology

Select an option
Nationwide analysis of sex differences in waiting times for cataract surgery in… Increasing Incidence of Posterior Uveal Melanoma in Scandinavia 1960-2022: A Tr… Development and Validation of a Deep Learning Algorithm for Differentiation of … Tailoring surveillance imaging in uveal melanoma based on individual metastatic… Melatonin Receptor Expression in Primary Uveal Melanoma The prognostic implication of visual acuity at the time of uveal melanoma diagn… Delays between Uveal Melanoma Diagnosis and Treatment Increase the Risk of Meta… Digital morphometry and cluster analysis identifies four types of melanocyte du… Overrepresentation of human epidermal growth factor receptor2 positive- and Lum… Improved Staging of Ciliary Body and Choroidal Melanomas Based on Estimation of… Sex-based differences in early and late uveal melanoma-related mortality No differences in the long-term prognosis of iris and choroidal melanomas when … No differences in the long-term prognosis of iris and choroidal melanomas when … Gain of Chromosome 6p Correlates with Severe Anaplasia, Cellular Hyperchromasia… Risk for Acute Myocardial Infarction After Ophthalmologic Procedures The long-term prognosis of patients with untreated primary uveal melanoma: A sy… Brachytherapy With 15- Versus 20-mm Ruthenium 106 Plaques Without Verification … Obesity paradox in uveal melanoma: high body mass index is associated with low … Multiorgan Involvement of Dormant Uveal Melanoma Micrometastases in Postmortem … A serum protein signature at the time of Uveal Melanoma diagnosis predicts long… Adjuvant melatonin for uveal melanoma (AMUM): protocol for a randomized open-la… Melatonin Receptor Expression in Primary Uveal Melanoma Prognostic implications of tenascin C in peripheral blood and primary tumours a…
Photo: Jens Sølvberg

Gustav Stålhammar, nominated as one of the emerging and promising young researchers from the Nordic countries.

Acta Board have been nominated Gustav Stålhammar as one of the emerging and promising young researchers from the Nordic countries.

followed by a session with four young speakers from the Scandinavian countries, each of whom will talk about their own research. We invite you to be one of these speakers.

On the occasion of the 100th of Acta anniversary in Maastricht in June, Gustav is invited together with Joni Turunen, Finland och Cecilie Bredrup, Norway to speak about their own research.

Title of Gustavs lecture is: ”Uveal melanoma past, present, and future -Towards adjuvant treatment”